Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POST MARKETING SURVEILLANCE TO OBSERVE SAFETY AND EFFECTIVENESS OF PAXLOVID IN PATIENTS, AND WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19

NCT05890612 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05890612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05890612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POST MARKETING SURVEILLANCE TO OBSERVE SAFETY AND EFFECTIVENESS OF PAXLOVID IN PATIENTS, AND WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19
Lead sponsor
Pfizer
Phase
Observational
Overall status
Recruiting
Start date
November 29, 2023
Completion date
February 17, 2029
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19